ChinaBio at JP Morgan: China Biopharma Books Strong 2020, Despite Pandemic

China 's biopharma industry continued to grow at a rapid pace in 2020, in spite of the formidable obstacle presented by COVID-19. Panelists at the China Showcase, a virtual event preceding the JP Morgan Healthcare Conference, believe the sector is strong, spurring record-setting levels investments, partnerships and initial public offerings. Just as important, they expect the growth to continue.  “The first half of 2020 was a stellar year for venture capital and innovative life sciences companies in China , and 2021 is on track to set new records across the board,” said moderator Greg Scott, founder and chairman of the ChinaBio® Group. More details....